A discovery tool for navigating peptide research by the outcome you're exploring. Each category surfaces the most relevant compounds, what the evidence currently supports, and where to read deeper.
83Peptides covered
12Application areas
3Evidence tiers
300+PubMed-linked references
Weight Loss & Metabolic Health
Established
The most rigorously studied peptide application by a wide margin. The GLP-1 and incretin co-agonist class has multiple Phase 3 RCTs, FDA-approved indications, and a deep cardiovascular and renal outcomes record.
An active research frontier with substantial animal-model data and growing — but still developing — controlled human trials. The community discussion typically runs ahead of the formal evidence base.
GH-axis peptides have legitimate biology — they reliably elevate growth hormone and IGF-1 — but the translation to body composition, strength, and recovery is more nuanced than community claims often suggest. Modest, real effects with attention to safety.
Among the most genuinely interesting research frontiers — but also the area where preclinical promise and controlled human evidence are most asymmetric. Mitochondrial-derived peptides, senolytics, and exercise-mimetic small molecules are advancing; clinical confirmation is mostly still ahead.
A mix of well-characterized neurobiology and trial literature with significant methodological caveats. Russian-origin synthetic peptides dominate the user discussion; cerebrolysin and davunetide carry larger but inconsistent trial portfolios.
A small but clinically meaningful category. PT-141 holds genuine FDA approval for hypoactive sexual desire disorder, supported by Phase 3 RECONNECT data. Other melanocortin compounds carry more variable evidence and safety profiles.
The most clinically established peptide effects in skin and cosmetic contexts are topical rather than systemic. Modest improvements in hydration, fine lines, and barrier function are supported by trials; "Botox in a jar" claims outpace the evidence.
An expanding research area with real translational interest. Antimicrobial peptides, immunomodulatory agents, and tissue-protective compounds form a credible cluster — though most are at earlier-stage human evidence than comparable indications elsewhere on this site.
A smaller but rigorously evidenced cluster of approved therapeutic peptides addressing bone, somatostatin, and vasopressin pathways. These are the longest-standing FDA-approved peptide drugs and a useful counterpoint to more speculative agents.
A peptide cluster targeted at sleep architecture, circadian regulation, and the anxiety-driven dimension of sleep difficulty. Mechanistically diverse; trial evidence is variable and most-rigorous for adjacent indications rather than insomnia per se.
Gut barrier biology is a layered system — mucus, epithelium, tight junctions, lamina propria, microbiome — and the peptide cluster targeting it spans approved drugs (teduglutide), Phase 3 candidates (larazotide), and active research compounds (BPC-157, KPV).
One way to navigate this space is by regulatory status. The peptides below are FDA-approved (in their labeled indications) and represent the highest-evidence-graded options on this site for each category. They are not necessarily the most-discussed in peptide-research communities — community popularity and regulatory evidence are different signals.
Peptides occupy very different positions on the clinical-credibility spectrum, and reading the field accurately requires keeping these distinctions in view. The hierarchy roughly:
FDA-approved with cardiovascular outcomes data — the strongest evidence tier; reserved for compounds with demonstrated effects on hard clinical endpoints (semaglutide's SELECT, liraglutide's LEADER).
FDA-approved within labeled indication — Phase 3 evidence for a specific use; the regulatory benchmark for any therapeutic claim. Most peptides on this site do not meet this bar.
Approved abroad, not FDA-approved — Cerebrolysin, Cortexin, and the Khavinson framework have international approval and clinical use in their jurisdictions, with evidence bases that vary in Western-grade rigor.
Active human clinical development — Phase 1–3 candidates without approval. Bimagrumab, retatrutide, apraglutide and others sit here.
Research-grade with thin or absent human RCT evidence — most BPC-157, TB-500, GHRH-analog community use sits here; the gap between the marketing language and the actual clinical evidence is largest in this tier.
Preclinical / theoretical only — interesting biology with no published human clinical trial data. DIHEXA, FOXO4-DRI, Adipotide, and many newly-discovered endogenous peptides occupy this position.
Reading any peptide claim well starts with placing the compound on this ladder. The same molecule can be appropriate for different audiences depending on which tier it actually occupies.
Where to read deeper
This page is a discovery tool — a way to find which peptides cluster around which goals. For deeper reading, the rest of the site organizes the same material along different axes:
Want the full per-compound research? The full peptide index has individual pages for every peptide on this site, each with structured evidence sections and PubMed-cited references.
Want to think about combinations? The Stacks section covers theoretical peptide combinations as discussed in research and biohacker communities, with explicit evidence-grading throughout.
Want to read calibrated takes on contested claims? The Evidence vs Myth section addresses specific over-claimed (and under-credited) areas in detail.
Want to track what's at the frontier? The Emerging Peptides section covers Phase 3 candidates, mid-stage compounds, and preclinical biology with explicit stage-marking.
Want the deepest hub on this site? The GLP-1 Hub is the most-developed area, with practical guides, drug-comparison articles, and emerging-research updates.
How to use this page
The categories above group peptides by the outcome people are typically researching. Each card surfaces featured compounds with one-line summaries — clicking through opens the full peptide page. The evidence chip tells you at a glance what kind of research base sits behind the category: established indications with multiple Phase 3 trials, active research with promising emerging human data, or emerging areas where most evidence is still preclinical. For a complete browse rather than a goal-driven view, see the full peptide index.